Workflow
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS
SERASera Prognostics(SERA) Prnewswire·2025-03-19 20:05

Core Viewpoint - Sera Prognostics Inc. reported its financial results for Q4 and full year 2024, highlighting a decrease in revenue and net loss, while emphasizing progress in its PRIME study and recent fundraising efforts to support its mission in maternal and neonatal health [1][3]. Financial Results Summary Fourth Quarter 2024 - Revenue for Q4 2024 was 24,000,downfrom24,000, down from 41,000 in Q4 2023 [4]. - Total operating expenses increased to 9.4million,a69.4 million, a 6% rise from 8.9 million in Q4 2023 [4]. - Research and development expenses were 3.1million,adecreaseofapproximately193.1 million, a decrease of approximately 19% compared to Q4 2023 [5]. - Selling, general and administrative expenses rose to 6.3 million from 5.0millioninQ42023,drivenbyincreasedspendingoncommercialactivities[5].−Thenetlossforthequarterwas5.0 million in Q4 2023, driven by increased spending on commercial activities [5]. - The net loss for the quarter was 8.6 million, compared to 7.9millionintheprior−yearquarter[5].FullYear2024−Totalrevenueforthefullyear2024was7.9 million in the prior-year quarter [5]. Full Year 2024 - Total revenue for the full year 2024 was 77,000, down from 306,000in2023[6].−Totaloperatingexpensesdecreasedto306,000 in 2023 [6]. - Total operating expenses decreased to 36.7 million from 40.1millionin2023[6].−Researchanddevelopmentexpensesfor2024were40.1 million in 2023 [6]. - Research and development expenses for 2024 were 14.7 million, down from 15.2millionin2023[8].−Selling,generalandadministrativeexpensesfor2024were15.2 million in 2023 [8]. - Selling, general and administrative expenses for 2024 were 21.9 million, significantly reduced from 24.7millionin2023[8].−Thenetlossfor2024was24.7 million in 2023 [8]. - The net loss for 2024 was 32.9 million, down from 36.2millionin2023[8].PRIMEStudyResults−ThePRIMEstudydemonstrateda2536.2 million in 2023 [8]. PRIME Study Results - The PRIME study demonstrated a 25% reduction in neonatal morbidity and mortality index (NMI) and an 18% reduction in neonatal length of hospital stay among the modified intent-to-treat population [7]. - A broader intent-to-treat population showed a 20% reduction in NMI and a 22% reduction in NICU admissions [7]. Fundraising and Future Plans - The company raised 57.5 million through a public follow-on offering in February 2025, extending its cash runway through 2028 [7][9]. - Proceeds will be used to expand commercial efforts in selected U.S. geographies, partner with payers and providers, and prepare for expansion in the European Union [7]. Company Overview - Sera Prognostics is focused on improving maternal and neonatal health through innovative pregnancy biomarker information [1][11]. - The PreTRM® Test is a key product that provides early risk prediction for spontaneous preterm birth, enabling proactive interventions [11][13].